News
CERS
2.620
+0.38%
0.010
Weekly Report: what happened at CERS last week (0914-0918)?
Weekly Report · 5d ago
Weekly Report: what happened at CERS last week (0907-0911)?
Weekly Report · 09/14 09:35
Weekly Report: what happened at CERS last week (0831-0904)?
Weekly Report · 09/07 09:33
Weekly Report: what happened at CERS last week (0824-0828)?
Weekly Report · 08/31 09:36
Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Kazia Therapeutics (KZIA) and Cerus (CERS)
TipRanks · 08/28 13:30
SpaceX continues to be Cathie's biggest bet; trims RBLX, PLTR, and AMD
Seeking Alpha · 08/24 11:07
Weekly Report: what happened at CERS last week (0817-0821)?
Weekly Report · 08/24 09:36
Cerus Price Target Announced at $6.50/Share by Freedom Broker
Dow Jones · 08/20 20:06
Cerus initiated with a Buy at Freedom Broker
TipRanks · 08/20 17:40
Cerus: This Blood-Safety Underdog Should Be Earning More Respect
Seeking Alpha · 08/18 14:34
Cathie Wood’s ARK Investment buys 255K shares of Cerus today
TipRanks · 08/17 11:05
Cathie Wood's Ark adds $30M Cloudflare, $27M Nvidia; cuts $60M Deere
Seeking Alpha · 08/17 10:15
Weekly Report: what happened at CERS last week (0810-0814)?
Weekly Report · 08/17 09:36
BTIG Remains a Buy on Cerus (CERS)
TipRanks · 08/14 11:36
Cerus Corporation Signals Confident Growth in Earnings Call
TipRanks · 08/14 00:08
Weekly Report: what happened at CERS last week (0803-0807)?
Weekly Report · 08/10 09:34
Weekly Report: what happened at CERS last week (0727-0731)?
Weekly Report · 08/03 09:34
Cerus Down Over 26%, On Pace for Largest Percent Decrease Since January 2023 -- Data Talk
Dow Jones · 07/31 17:01
Midday Fly By: Apple sinks after guidance, Amazon’s AWS powers beat
TipRanks · 07/31 16:17
Friday's ETF Movers: GXUS, ARKK
NASDAQ · 07/31 16:03
More
Webull provides a variety of real-time CERS stock news. You can receive the latest news about Cerus through multiple platforms. This information may help you make smarter investment decisions.
About CERS
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.